Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study.

نویسندگان

  • Pedro J García Ruiz
  • Angel Sesar Ignacio
  • Begoña Ares Pensado
  • Alfonso Castro García
  • Fernando Alonso Frech
  • Mercedes Alvarez López
  • José Arbelo González
  • Joan Baiges Octavio
  • Juan Andrés Burguera Hernández
  • Matilde Calopa Garriga
  • Dulce Campos Blanco
  • Belén Castaño García
  • Manuel Carballo Cordero
  • José Chacón Peña
  • Anna Espino Ibáñez
  • Aránzazu Gorospe Onisalde
  • Santiago Giménez-Roldán
  • Pilar Granés Ibáñez
  • Jorge Hernández Vara
  • Ramón Ibáñez Alonso
  • Félix Javier Jiménez Jiménez
  • Jerzy Krupinski
  • Jaime Kulisevsky Bojarsky
  • Inés Legarda Ramírez
  • Elena Lezcano García
  • Juan Carlos Martínez-Castrillo
  • Dolores Mateo González
  • Francesc Miquel Rodríguez
  • Pablo Mir
  • Elena Muñoz Fargas
  • José Obeso Inchausti
  • Jesús Olivares Romero
  • José Olivé Plana
  • Pilar Otermin Vallejo
  • Berta Pascual Sedano
  • Víctor Pérez de Colosía Rama
  • Isabel Pérez López-Fraile
  • Albert Planas Comes
  • Víctor Puente Periz
  • María Cruz Rodríguez Oroz
  • Dolores Sevillano García
  • Pilar Solís Pérez
  • José Suárez Muñoz
  • Julia Vaamonde Gamo
  • Caridad Valero Merino
  • Francesc Valldeoriola Serra
  • José Miguel Velázquez Pérez
  • Rosa Yáñez Baña
  • Ivana Zamarbide Capdepon
چکیده

Continuous subcutaneous apomorphine infusion (CSAI) is, at present, an alternative option for advanced Parkinson's disease (PD) with motor fluctuations. We studied the evolution of patients with PD and severe motor fluctuations long-term treated with CSAI. We reviewed data from 82 patients with PD (mean age, 67 +/- 11.07; disease duration, 14.39 +/- 5.7 years) and severe motor fluctuations referred to 35 tertiary hospitals in Spain. These patients were long-term treated (for at least 3 months) with CSAI and tolerated the procedure without serious side effects. We compared the baseline data of these 82 patients (before CSAI) with those obtained from the last follow-up visit of each patient. The mean follow-up of CSAI was 19.93 +/- 16.3 months. Mean daily dose of CSAI was 72.00 +/- 21.38 mg run over 14.05 +/- 1.81 hours. We found a statistically significant reduction in off-hours, according to self-scoring diaries (6.64 +/- 3.09 vs. 1.36 +/- 1.42 hours/day, P < 0.0001), total and motor UPDRS scores (P < 0.0001), dyskinesia severity (P < 0.0006), and equivalent dose of antiparkinsonian therapy (1,405 +/- 536.7 vs. 800.1 +/- 472.9 mg of levodopa equivalent units P < 0.0001). CSAI is an effective option for patients with PD and severe fluctuations, poorly controlled by conventional oral drug treatment.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up.

OBJECTIVES Despite the recent introduction of new peroral drugs as well as neurosurgical methods for Parkinson's disease, treatment of late stage parkinsonian patients remains difficult and many patients become severely handicapped because of fluctuations in their motor status. Injections and infusions of apomorphine has been suggested as an alternative in the treatment of these patients, but t...

متن کامل

[Subcutaneous apomorphine in the treatment of Parkinson's disease].

Motor and psychiatric complications are the main limitations for chronic treatment with levodopa in patients with Parkinson's disease (PD). Apomorphine (APM) is a potent D1 and D2 dopaminergic agonist that has been proven useful in the management of PD. Ten patients with complicated PD involving fluctuations in mobility and dyskinesia were treated with subcutaneous APM (1 with continuous infusi...

متن کامل

Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection.

Long-term oral therapy with levodopa is associated with the development of motor fluctuations and dyskinesia in a large percentage of patients with Parkinson's disease (PD). Motor complications are associated with a number of non-motor symptoms and have a negative impact on disability and quality of life. There are three therapeutic options available for the management of patients at this advanc...

متن کامل

A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.

BACKGROUND As Parkinson's disease (PD) progresses,despite optimized pharmacotherapy, patients experience more frequent fluctuations between symptomatic improvement ("on" times) and the return of motor features ("off" times). Apomorphine, the first injectable dopamine agonist available in the United States, is indicated for the acute treatment of "off" episodes (eg, end-of-dose wearing-off episo...

متن کامل

When the going gets tough: how to select patients with Parkinson's disease for advanced therapies.

Levodopa-induced motor complications of Parkinson's disease, including motor fluctuations and dyskinesias, become increasingly frequent as the disease progresses, and are often disabling. Oral and transdermal therapies have limited efficacy in controlling these problems. Advanced device-aided therapies, including continuous infusion of apomorphine, deep brain stimulation and levodopa-carbidopa ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Movement disorders : official journal of the Movement Disorder Society

دوره 23 8  شماره 

صفحات  -

تاریخ انتشار 2008